Hanchung Medical announced in October that it has signed an exclusive distribution agreement for its PDLLA (Poly-D,L-lactic acid)-based collagen stimulator, Etherics 200mg PDLLA, covering the markets of Azerbaijan and Georgia. Under the agreement, product registration, distribution, and product introduction to medical institutions in both countries will be carried out in stages.

Hanchung Medical stated,
“Through close collaboration with our local partners, we plan to establish a stable supply chain and expand distribution to medical institutions through designated channels during the initial launch phase.”

According to the brand, Etherics 200mg PDLLA is supplied in a 200mg PDLLA powder formulation. Key product information includes a recommended treatment interval of 4–6 weeks, an expected duration of 18 to 24 months (depending on individual variation), a storage temperature of 1–30°C, and a shelf life of 36 months. Actual use must comply with each country’s regulatory approvals, labeling requirements, and IFU (Instructions for Use).

A Hanchung Medical representative commented,
“Europe is a growing market for aesthetic and regenerative medicine. By prioritizing regulatory-compliant product information and post-market support, and leveraging our educational content and partnership capabilities, we aim to establish a strong presence in the region.”